The estimated Net Worth of Jonathan Mark Hopper is at least $3.56 Миллион dollars as of 3 September 2024. Dr Hopper owns over 10,000 units of Vericel Corp stock worth over $2,981,607 and over the last 9 years he sold VCEL stock worth over $0. In addition, he makes $578,360 as Chief Medical Officer at Vericel Corp.
Dr has made over 18 trades of the Vericel Corp stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of VCEL stock worth $109,500 on 3 September 2024.
The largest trade he's ever made was exercising 43,264 units of Vericel Corp stock on 21 December 2020 worth over $473,741. On average, Dr trades about 7,443 units every 61 days since 2016. As of 3 September 2024 he still owns at least 68,229 units of Vericel Corp stock.
You can see the complete history of Dr Hopper stock trades at the bottom of the page.
Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. is the Chief Medical Officer at Vericel Corp.
As the Chief Medical Officer of Vericel Corp, the total compensation of Dr B at Vericel Corp is $578,360. There are 4 executives at Vericel Corp getting paid more, with Dominick Colangelo having the highest compensation of $5,385,530.
Dr B is 59, he's been the Chief Medical Officer of Vericel Corp since . There are 5 older and 7 younger executives at Vericel Corp. The oldest executive at Vericel Corp is Robert Zerbe, 69, who is the Independent Chairman of the Board.
Jonathan's mailing address filed with the SEC is 64 SIDNEY STREET, , CAMBRIDGE, MA, 02139.
Over the last 10 years, insiders at Vericel Corp have traded over $9,831,645 worth of Vericel Corp stock and bought 890 units worth $10,297 . The most active insiders traders include Dominick Colangelo, Gerard J Michel и Kevin F Mclaughlin. On average, Vericel Corp executives and independent directors trade stock every 17 days with the average trade being worth of $567,401. The most recent stock trade was executed by Steven C Gilman on 4 September 2024, trading 5,000 units of VCEL stock currently worth $18,700.
about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea
Vericel Corp executives and other stock owners filed with the SEC include: